Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neurotech International Ltd (NTI.AX)

Neurotech International Ltd (NTI.AX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Neurotech International Ltd 55 Collins Street Suite 102, Level 1 Melbourne VIC 3000 AUS

https://www.neurotechinternational.com P: +61 394983132 F: +61 893893199

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

Neurotech International Ltd is a clinical-stage biopharmaceutical development company. It is focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. NTI164 is a proprietary broad-spectrum cannabinoid drug candidate with a safety and efficacy profile across several paediatric neurological conditions with high unmet need. The group is working across various clinical programs, which include Autism Spectrum Disorder (ASD), Rett Syndrome, PANDAS/PANS, and Human Pharmacokinetics. It is conducting clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.

Key Statistics

Overview:

Market Capitalization, $K 18,148
Shares Outstanding, K 1,296,313
% of Institutional Shareholders 0.05%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -10,599 K

Growth:

1-Year Return -66.67%
3-Year Return -73.08%
5-Year Return -80.28%
5-Year Revenue Growth -68.79%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm -0.01
Dividend Payout Ratio 0.00%

NTI.AX Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Return-on-Equity % -142.71%
Return-on-Assets % -137.17%
Profit Margin % -4,453,302.10%
Debt/Equity N/A
Price/Sales 60,934.79
Price/Book 6.14
Book Value/Share 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar